NREP
NEW REPRESENTATIVE AT IB RECEIVED
23/01/2025
Voltar para busca
Dado oficial do USPTO
ETHYPHARM INNOVATIVE DRUG DELIVERY
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
43
Atualização mais recente
23/01/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 42
Data de depósito
21/04/2011
Data de registro
24/07/2012
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/02/2023
Última transação
23/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
FR
Examinador
ANKRAH, NAAKWAMA
Unidade examinadora
L90
Localização atual
GENERIC WEB UPDATE
Descrição da marca
The mark consists of the word "Ethypharm" in block letters (the letter "E" is in upper case and the other letters are in lower case), which is plum (Pantone 262 C) in color; under the name "Ethypharm" there is a blue (Pantone Process Blue C) horizontal line to the left and the three words "INNOVATIVE DRUG DELIVERY" in small capital letters to the right, which are plum (Pantone 262 C) in color; to the left of these elements there is an upside-down exclamation mark, which is plum (Pantone 262 C) in color, surrounded by a blue (Pantone Process Blue C) crescent.
Titulares e representantes
Titulares
ETHYPHARM
Representantes
Thomas W. Brooke Holland & Knight LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of cancercentral nervous system disorderhormonal disordermetabolic disorderimmunologic disordercardiovascular system disorderinfectionpainaddictionophthalmological disordergynecological disorderdermatological disorder; veterinary preparations for the treatment of animal diseasein the nature of cancercentral nervous system disorderhormonal disordermetabolic disorderimmunologic disordercardiovascular system disorderinfectionpainaddictionophthalmological disordergynecological disorderdermatological disorder; sanitary preparations for medical purposesalkaline solutionchloridetensioactive substanceiodine; Dietary food supplementsprotein supplementsinfant formulaspreparation of herbal origin to be used for slimnesscleansing digestioncirculation and relaxationvitaminsmineralslecithinmeal replacement in the form of barsdrinks and capsules; Disinfectants pertaining to the pharmaceutical sectoralkaline solutionchloridetensioactive substanceiodine for hygienic purposes
Classe 42
Research and development of new technologies in the medical and pharmaceutical fields; research and development in the field of galenic innovation; research and development in the field of medical solutions; medical and clinical studiesscientific research services for medical purposes; research and development for others in the medical and pharmaceutical fields; engineering in the medical and pharmaceutical fields; chemical research; chemical analysis
Publicações
Histórico de despachos e eventos da marca no USPTO.
43 publicações encontradas
NREP
NEW REPRESENTATIVE AT IB RECEIVED
27/12/2024
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
05/11/2023
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
16/10/2023
INPC
INVALIDATION PROCESSED
16/10/2023
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
10/10/2023
C71T
CANCELLED SECTION 71
10/02/2023
RNWL
INTERNATIONAL REGISTRATION RENEWED
03/06/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
15/05/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/12/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/11/2019
NREP
NEW REPRESENTATIVE AT IB RECEIVED
13/12/2018
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - MAILED
14/08/2018
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
14/08/2018
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/08/2018
ES75
TEAS SECTION 71 & 15 RECEIVED
24/07/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
19/03/2013
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/10/2012
FIMP
FINAL DISPOSITION PROCESSED
26/10/2012
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
24/10/2012
R.PR
REGISTERED-PRINCIPAL REGISTER
24/07/2012
PUBO
PUBLISHED FOR OPPOSITION
08/05/2012
NPUB
NOTICE OF PUBLICATION
18/04/2012
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
04/04/2012
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/04/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/03/2012
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/03/2012
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/03/2012
CNRT
NON-FINAL ACTION MAILED
17/01/2012
CNRT
NON-FINAL ACTION WRITTEN
16/01/2012
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/12/2011
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/12/2011
ALIE
ASSIGNED TO LIE
14/12/2011
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/12/2011
RFNT
REFUSAL PROCESSED BY IB
20/08/2011
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/08/2011
RFRR
REFUSAL PROCESSED BY MPU
03/08/2011
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/08/2011
CNRT
NON-FINAL ACTION WRITTEN
02/08/2011
DOCK
ASSIGNED TO EXAMINER
01/08/2011
MAFR
APPLICATION FILING RECEIPT MAILED
28/06/2011
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
24/06/2011
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
23/06/2011
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ETHYPHARM INNOVATIVE DRUG DELIVERY ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.